Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension

Summary

This study is designed to investigate whether sympathoinhibition with moxonidine could provide added metabolic benefit compared to the second line therapy in the current guidelines.

Timeline

Start

2015-06-24

Primary completion

2024-02-24

Completion

2024-06-24

Publications

• Background Carnagarin R, Gregory C, Azzam O, Hillis GS, Schultz C, Watts GF, Bell D, Matthews V, Schlaich MP. The Role of Sympatho-Inhibition in Combination Treatment of Obesity-Related Hypertension. Curr Hypertens Rep. 2017 Oct 28;19(12):99. doi: 10.1007/s11906-017-0795-1.

Drugs

Indications